TERMS OF USE

This Web site is operated and maintained by ThromboGenics, Inc., (“ThromboGenics”) for general informational and educational purposes. Please carefully read and review the Terms of Use Agreement below before accessing or using this Web site. Your use of this Web site constitutes your acceptance without modification of the terms, conditions, and notices contained herein and all applicable laws. If you do not agree with the Terms of Use Agreement, you may not access or use this Web site.

  1. Use of Web Site.Your access to and use of this Web site is subject to this Terms of Use Agreement. By accessing and browsing this Web site, you accept, without limitation or qualification, this Terms of Use Agreement. You may freely browse this Web site, but may only access and use such information and content for personal, noncommercial use. You may not modify the Web site or its contents; create derivative work based on this Web site or its contents; remove copyright notices or other proprietary rights notices contained in the Web site or its content; use any meta tags or any other “hidden text” using the ThromboGenics name or trademarks without express written consent; or use software robots, spiders, crawlers, or similar data gathering and extraction tools, or engage in any other conduct that may unreasonably burden our infrastructure.
  2. Content.This Web site was developed as a service of ThromboGenics. ThromboGenics will use reasonable efforts to include accurate and current information on this Web site, but makes no warranties or representations of any kind as to its accuracy, currency, or completeness. You agree that access to and use of this Web site, and the content and information within, is at your own risk.

    Nothing on this Web site should be construed as the giving of advice or the making of a recommendation, and it should not be relied upon as the basis for any decision or action. Should you have a medical condition, promptly see your own medical doctor or health care provider. We do not offer or provide any patient-specific information or personal medical diagnosis. Please discuss your medical information with a qualified physician.

    Nothing on this Web site shall constitute an offer or solicitation to invest, purchase, dispose of, trade, deal, or transact in any manner in the securities of any ThromboGenics affiliate. Investors must not rely on any information on this Web site for investment decisions.

  3. Copyrights.The entire contents of this Web site are subject to copyright protection. Copyright © 2012 ThromboGenics, Inc. You should assume that everything you see or read on this Web site is copyrighted unless otherwise noted and may not be used except as provided within this Terms of Use Agreement or with the express, prior written consent of ThromboGenics. You must retain and reproduce each and every copyright or other proprietary rights notice contained in any information you use or download. ThromboGenics neither warrants nor represents that your use of the information and content on this Web site will not infringe rights of third parties not owned by or affiliated with ThromboGenics. With the exception of the above permission, nothing contained within this Terms of Use Agreement shall be construed as conferring, by implication, estoppel, or otherwise, any license or right under any patent or trademark of ThromboGenics or any third party. Similarly, except as expressly provided above, nothing contained within this Terms of Use Agreement shall be construed as conferring any license or right under any ThromboGenics copyright.

    You are strictly prohibited from quoting, distributing, transmitting, modifying, reposting, reusing, duplicating, copying, selling, reselling, accessing, or displaying the information or content contained within this Web site for commercial purposes without the express, prior written consent of ThromboGenics.

  4. Privacy. ThromboGenics respects the privacy of its Web site users. ThromboGenics will only collect your personally identifiable information, such as your name, address, telephone number, or email address, when you provide it to us at this Web site. ThromboGenics will not sell or otherwise transfer such information to any third parties for their own use, unless otherwise noted. Using various analysis technologies, including cookies, ThromboGenics may collect nonpersonally identifiable information about how you use our Web site. These analysis technologies may be provided by third parties. Information that might be collected using these technologies includes, for example, the pages you visit on our Web site, the paths you take within our sites, and the length of time that you spend on our Web sites. We use this information as a whole to improve the quality of our Web sites.

    This Web site is not intended or designed to attract children under the age of 13. We do not collect personally identifiable information from any person we know to be under the age of 13.

    For more information about how ThromboGenics protects the privacy of its Web site users, please refer to the ThromboGenics, Inc., Privacy Statement.

    The Privacy Policy and provisions described here do not apply to third-party Web sites linked from this Web site. Please be sure to review the individual terms of use and privacy policies that accompany such sites. ThromboGenics reserves the right to revise its Privacy Policy as necessary to disclose any changes or modification in our practices and policies.

  5. Warranties and Limitation of Liability. ThromboGenics accepts no liability for the accuracy, completeness, or use of the information on this Web site. All information is provided “AS IS” WITHOUT WARRANTY OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT. THROMBOGENICS DOES NOT WARRANT OR REPRESENT THAT THIS WEB SITE OR ITS SERVER(S) ARE FREE OF VIRUSES, MALWARE, OR OTHER HARMFUL COMPONENTS. Some jurisdictions do not allow the exclusion of implied warranties, so the above exclusions may not apply to you. THROMBOGENICS ASSUMES NO LIABILITY AND SHALL NOT BE LIABLE FOR ANY DIRECT, SPECIAL, INDIRECT, OR CONSEQUENTIAL DAMAGES, OR ANY OTHER KIND OF DAMAGES OF ANY KIND INCLUDING, BUT NOT LIMITED TO, LOSS OF USE, LOSS OF PROFITS, OR LOSS OF DATA, WHETHER IN AN ACTION IN CONTRACT, TORT (INCLUDING, BUT NOT LIMITED TO, NEGLIGENCE), OR OTHERWISE, ARISING OUT OF THE USE OF OR IN ANY WAY CONNECTED WITH THE USE OF THIS WEB SITE OR THE INFORMATION AND CONTENT CONTAINED ON, OR ACCESSED THROUGH, THIS WEB SITE. ThromboGenics reserves the right to discontinue this Web site at any time without notice and without liability.

  6. Third-Party Links. ThromboGenics has not reviewed any or all of the third-party Web sites which contain links to this Web site and is not responsible for the content of such off-site pages linked to this site. If you wish to link to this Web site, you may only link to the home page; you must request prior written consent from ThromboGenics to link to any other pages within this Web site. Links to third-party Web sites are provided for the interest and convenience of visitors to this Web site only. We will endeavor to inform users when they are leaving this Web site and traveling to third-party Web sites. We do not express any opinion on the content or information of any third-party Web site and expressly disclaim any liability arising from the use of any and all third-party Web site information and content.

  7. Consequences. If we become aware that a user has violated any of the terms and conditions contained in this Terms of Use Agreement, we may immediately take corrective action, including preventing the user from using the services of the ThromboGenics Web site and removing any data, information, and content improperly utilized by the user, at any moment and without notice. ThromboGenics will not hesitate to seek damages from a user if ThromboGenics has been injured by a violation of this Terms of Use Agreement in any way. You agree to indemnify, defend, and hold harmless ThromboGenics, its officers, directors, employees, agents, suppliers, and third-party partners from and against all losses, expenses, damages, and costs, including reasonable attorneys’ fees, resulting from any violation by you of this Terms of Use Agreement.

  8. Disputes. If any dispute arises between you and ThromboGenics concerning these Terms or your use of this Web site, it shall first be resolved through good-faith negotiations. If such negotiations are unsuccessful, the disputes shall be submitted to confidential arbitration pursuant to the Federal Arbitration Act, 9 U.S.C. § 1 et seq. Arbitration shall be conducted under the rules of the American Arbitration Association. The governing law shall be New Jersey. The arbitrator’s award shall be binding and may be entered as a judgment in any court of competent jurisdiction. However, to the extent that you have violated or threatened to violate our intellectual property rights in any manner, we may seek injunctive or other appropriate relief in New Jersey courts.

  9. Revisions. ThromboGenics reserves the right to revise this Terms of Use Agreement at any time by updating this page. All users are bound by any revisions and should therefore periodically visit this page to review the current binding Terms of Use Agreement.

Contact Us

Please fill out the form below.
* denotes a required field.

Important Safety Information

Click to Expand
Indication

JETREA® (ocriplasmin) injection, for Intravitreal Injection, 1.25mg/mL is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.

Important Safety Information
Warnings and Precautions
  • A decrease of ≥ 3 lines of best-corrected visual acuity (BCVA) was experienced by 5.6% of patients treated with JETREA and 3.2% of patients treated with vehicle in the controlled trials. The majority of these decreases in vision were due to progression of the condition with traction and many required surgical intervention. Patients should be monitored appropriately.
  • Intravitreal injections are associated with intraocular inflammation/infection, intraocular hemorrhage and increased intraocular pressure (IOP). Patients should be monitored and instructed to report any symptoms without delay. In the controlled trials, intraocular inflammation occurred in 7.1% of patients injected with JETREA vs 3.7% of patients injected with vehicle. Most of the post-injection intraocular inflammation events were mild and transient. If the contralateral eye requires treatment with JETREA, it is not recommended within 7 days of the initial injection in order to monitor the post-injection course in the injected eye.
  • Potential for lens subluxation.
  • In the controlled trials, the incidence of retinal detachment was 0.9% in the JETREA group and 1.6% in the vehicle group, while the incidence of retinal tear (without detachment) was 1.1% in the JETREA group and 2.7% in the vehicle group. Most of these events occurred during or after vitrectomy in both groups.
  • Dyschromatopsia (generally described as yellowish vision) was reported in 2% of all patients injected with JETREA. In approximately half of these dyschromatopsia cases there were also electroretinographic (ERG) changes reported (a- and b-wave amplitude decrease).
Adverse Reactions
  • The most commonly reported reactions (≥ 5%) in patients treated with JETREA were vitreous floaters, conjunctival hemorrhage, eye pain, photopsia, blurred vision, macular hole, reduced visual acuity, visual impairment, and retinal edema.

To report SUSPECTED ADVERSE REACTIONS, contact ThromboGenics Inc. at 1-855-253-7396 [OPTION 2] or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

You may also report side effects of JETREA online directly to ThromboGenics by clicking here if you are a Patient or here if you are a Health Care Professional.

References:
1. JETREA [package insert]. Iselin, NJ: ThromboGenics, Inc.; 2017. 2. Stalmans P, Lescrauwaet B, Blot K. A retrospective cohort study in patients with diseases of the vitreomacular interface (ReCoVit). Poster presented at: The Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting; May 4-8, 2014; Orlando, Florida.